Better health for patients.
Smarter solutions for Pharma.
Better health for patients.
Smarter solutions for Pharma.
Who we are
Who we are
Tithonia is an entrepreneurial life sciences group that looks at the world differently.
Our values of agency, knowledge and transparency, first principles thinking, and humility allow us to solve the toughest problems by empowering our team to lead with purpose.
This approach, combined with our ways of working and focus on innovation, is proven to allow our brands to flourish in an otherwise complex landscape. We challenge the status quo and seek to create smarter solutions for pharma, which in turn delivers better health for patients.
Androlabs
The first global pharmaceutical company dedicated to men’s health. On a mission to close the male life expectancy gap.
Androlabs
The first global pharmaceutical company dedicated to men’s health. On a mission to close the male life expectancy gap.
Tamrisa
A specialized pharma venture to tackle anti-microbial resistance through innovation, stewardship and access.
Tamrisa
A specialized pharma venture to tackle anti-microbial resistance through innovation, stewardship and access.
Simple Pharma
Simplifying the complex world of pharma operations and providing a platform for products to thrive.
Simple Pharma
Simplifying the complex world of pharma operations and providing a platform for products to thrive.
Nicolas Vennin, Co-Founder
Charlie Bryant, Co-founder & CEO
Headquartered in London, Tithonia was founded in 2021 by Charlie Bryant and Nicolas Vennin, two entrepreneurs who spotted an opportunity to build a different kind of pharma company.
Their vision was to turn the traditional pharma model on its head. Instead of focusing on sales and top line growth, they started by building a company whose focus is on razor-sharp operations. Simple Pharma was born, a pharmaceutical platform company that holds licences and distributes medicines in 30+ countries across Europe and worldwide.
In 2022, Tithonia launched Androlabs, a specialty men's health pharma company whose mission is to close the male life expectancy gap. By providing the infrastructure for the products to reach the market with Simple Pharma, Tithonia enables Androlabs to fully focus on adding value to prescribers and patients. Androlabs was able to grow organically by more than 30% in its first two full years of trading.
In 2024, Tithonia partnered with Tamrisa, an entrepreneurial pharma company focused on tackling anti-microbial resistance. The story continues.
At Tithonia, we champion good, profitable growth, which is driven by combining our core values with a relentless focus on innovation and execution. Our core capabilities include strategic leadership, functional expertise, capital allocation, and identifying market opportunities for value creation.
The combined team stands at 40+ people, spread across 7 countries.
Nicolas Vennin, Co-Founder
Charlie Bryant, Co-founder & CEO
Our story
Our story
Headquartered in London, Tithonia was founded in 2021 by Charlie Bryant and Nicolas Vennin, two entrepreneurs who spotted an opportunity to build a different kind of pharma company.
Their vision was to turn the traditional pharma model on its head. Instead of focusing on sales and top line growth, they started by building a company whose focus is on razor-sharp operations. Simple Pharma was born, a pharmaceutical platform company that holds licences and distributes medicines in 30+ countries across Europe and worldwide.
In 2022, Tithonia launched Androlabs, a specialty men's health pharma company whose mission is to close the male life expectancy gap. By providing the infrastructure for the products to reach the market with Simple Pharma, Tithonia enables Androlabs to fully focus on adding value to prescribers and patients. Androlabs was able to grow organically by more than 30% in its first two full years of trading.
In 2024, Tithonia partnered with Tamrisa, an entrepreneurial pharma company focused on tackling anti-microbial resistance. The story continues.
At Tithonia, we champion good, profitable growth, which is driven by combining our core values with a relentless focus on innovation and execution. Our core capabilities include strategic leadership, functional expertise, capital allocation, and identifying market opportunities for value creation.
The combined team stands at 40+ people, spread across 7 countries.
Why us?
Our strategy is driven by four capabilities:
Acquisitions and integrations - our team has overseen several large-scale acquisitions and integrations of pharmaceutical products, bringing them onto our platform
Organic growth of specialty pharmaceutical products - our playbook allows products to reach their full potential
Lean operations - we manage scale and growth with tech-enabled, lean pharmaceutical operations
Pharmaceutical product development - we use our deep domain knowledge in our therapy areas to bring innovative products to patients.
7
Locations across Europe
7
Locations across Europe
>30%
Annual revenue growth
>30%
Annual revenue growth
40+
Team members
40+
Team members
Our strategy is driven by four capabilities:
Acquisitions and integrations - our team has overseen several large-scale acquisitions and integrations of pharmaceutical products, bringing them onto our platform.
Organic growth of specialty pharmaceutical products - our playbook allows products to reach their full potential.
Lean operations - we manage scale and growth with tech-enabled, lean pharmaceutical operations.
Pharmaceutical product development - we use our deep domain knowledge in our therapy areas to bring innovative products to patients.
Why us?
40+
Team members
7
Locations across Europe
>30%
Annual revenue growth